XENOBIOTICA

Scope & Guideline

Transforming Knowledge on Xenobiotic Effects.

Introduction

Welcome to your portal for understanding XENOBIOTICA, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0049-8254
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1971 to 2024
AbbreviationXENOBIOTICA / Xenobiotica
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

XENOBIOTICA focuses on the pharmacokinetics, metabolism, and toxicology of xenobiotics, particularly in the context of drug development and safety assessment. The journal aims to provide a platform for innovative research that enhances the understanding of drug disposition and interactions, with a strong emphasis on translational science.
  1. Pharmacokinetic Studies:
    The journal publishes research on the absorption, distribution, metabolism, and excretion (ADME) of drugs and other xenobiotics, highlighting methodologies to investigate these processes in various biological systems.
  2. Drug Metabolism and Toxicology:
    A significant focus is placed on the metabolic pathways of drugs, including the role of cytochrome P450 enzymes and other metabolic processes, as well as the associated toxicity and safety profiles.
  3. Predictive Modeling and Simulation:
    XENOBIOTICA supports the use of in silico and physiologically based pharmacokinetic (PBPK) modeling to predict human pharmacokinetics and drug-drug interactions, thereby facilitating more effective drug development.
  4. Comparative Metabolism:
    The journal explores species differences in drug metabolism, providing insights into the relevance of animal models in predicting human outcomes, which is critical for regulatory submissions.
  5. Biotransformation Workshops and Reports:
    The journal includes meeting reports and special editions related to biotransformation workshops, fostering collaboration and dissemination of cutting-edge research in drug metabolism.
XENOBIOTICA is experiencing a dynamic evolution in its research themes, with several emerging topics gaining traction in recent publications. These trends reflect the journal's responsiveness to advancements in drug development and the need for improved safety assessments.
  1. Machine Learning and AI in Drug Development:
    Recent publications have increasingly focused on the application of machine learning and artificial intelligence for predicting ADME properties and drug interactions, showcasing the potential for these technologies to enhance efficiency in drug development.
  2. Precision Medicine and Pharmacogenomics:
    There is a growing emphasis on studies that examine genetic polymorphisms and their impact on drug metabolism and pharmacokinetics, aligning with the broader trend towards personalized medicine.
  3. Advanced Drug Delivery Systems:
    Research on novel drug formulations and delivery methods, particularly those that enhance bioavailability and patient compliance, is on the rise, indicating a shift towards practical applications in clinical settings.
  4. Integration of In Vitro and In Vivo Models:
    An emerging trend is the integration of in vitro and in vivo studies to provide more comprehensive insights into drug metabolism and pharmacokinetics, reflecting a desire for more translational research that can inform clinical practices.

Declining or Waning

While XENOBIOTICA continues to thrive in its core focus areas, certain themes have seen a noticeable decline in recent years. This may reflect shifts in research priorities or the completion of previously explored topics.
  1. Traditional Toxicology Studies:
    There has been a decrease in the publication of traditional toxicology studies that do not leverage modern methodologies or predictive modeling, as the field moves towards more integrated and innovative approaches.
  2. Non-Pharmacokinetic Studies:
    Papers focusing on non-pharmacokinetic aspects of drug action, such as purely pharmacodynamic studies without a pharmacokinetic context, are becoming less common, indicating a shift towards more comprehensive studies that integrate both aspects.
  3. Basic In Vitro Studies:
    The journal has seen a decline in basic in vitro studies that do not contribute new insights into drug mechanisms or metabolism. The emphasis is now on more complex models that better simulate in vivo conditions.

Similar Journals

BIOPHARMACEUTICS & DRUG DISPOSITION

Catalyzing Progress in Pharmacology and Drug Disposition
Publisher: WILEYISSN: 0142-2782Frequency: 6 issues/year

BIOPHARMACEUTICS & DRUG DISPOSITION, published by WILEY, is a prominent journal in the fields of biopharmaceutics and pharmacology, dedicated to the dissemination of vital research that spans from the foundational aspects of drug disposition to advanced therapeutic developments. Since its inception in 1979, this journal has established itself as a crucial resource for a diverse audience, including researchers, professionals, and students. With its impact factor indicating solid performance and a current ranking in Q2 for Pharmaceutical Science and Q3 across miscellaneous medicine categories, BIOPHARMACEUTICS & DRUG DISPOSITION serves as a nexus for innovative studies and breakthrough findings. The journal's comprehensive scope ensures that rigorous scientific inquiry is represented, helping to advance the understanding of drug behavior in biological systems. Participating in this scholarly dialogue not only enhances individual knowledge but contributes to the broader pharmaceutical and medical communities, making it an essential publication for all stakeholders interested in drug development and utilization.

AAPS PHARMSCITECH

Advancing Pharmaceutical Innovations for a Healthier Tomorrow
Publisher: SPRINGERISSN: 1530-9932Frequency: 1 issue/year

AAPS PHARMSCITECH is a prestigious peer-reviewed journal published by Springer, focusing on the dynamic field of pharmaceutical sciences and technology. With an ISSN of 1530-9932, it provides a vital platform for disseminating cutting-edge research that spans key areas including drug discovery, pharmacology, toxicology, and ecological impacts of pharmaceuticals. The journal is recognized for its rigorous scientific contributions, currently holding a commendable Q2 quartile ranking across several relevant categories, including Agronomy and Crop Science, Aquatic Science, and Medicine in 2023. Notably, it ranks 43rd out of 183 in the Scopus Pharmacology, Toxicology, and Pharmaceutics category, placing it in the 76th percentile of its field. Aiming to foster innovation and collaboration among researchers, professionals, and students, AAPS PHARMSCITECH is committed to advancing scientific knowledge and addressing contemporary challenges in pharmaceutical sciences. The journal offers various access options to ensure wide dissemination of research findings, making it an essential resource for those dedicated to enhancing public health through pharmaceutical advancements.

AAPS Journal

Shaping the Future of Pharmaceutical Research and Applications.
Publisher: SPRINGERISSN: 1550-7416Frequency: 1 issue/year

AAPS Journal, published by Springer in the United States, is a leading peer-reviewed journal dedicated to the advancement of research in the field of Pharmaceutical Sciences. With an impressive Q1 rank in its category and a position within the 81st percentile of Scopus rankings, it serves as a vital resource for researchers and professionals seeking to disseminate impactful findings and innovative methodologies. The journal publishes high-quality original research, review articles, and technical reports aimed at addressing the multifaceted challenges in pharmacology, toxicology, and pharmaceutics. Operating under an Open Access model, AAPS Journal ensures broad dissemination of knowledge, contributing to the enhanced visibility and accessibility of research outputs. With a publication window spanning from 1999 to 2024, it continues to shape the future of pharmaceutical research and its applications. Researchers, students, and industry professionals will find a valuable repository of cutting-edge knowledge in this esteemed journal.

Journal of Pharmaceutical Analysis

Elevating knowledge in pharmaceutical analysis for a global impact.
Publisher: ELSEVIERISSN: 2095-1779Frequency: 12 issues/year

Journal of Pharmaceutical Analysis is a premier open-access journal published by ELSEVIER, dedicated to advancing the field of pharmaceutical sciences. Since its inception in 2011, this journal has become a vital resource for researchers, professionals, and students, with a focus on analytical chemistry, drug discovery, and electrochemistry, among other subjects. With an impressive impact factor reflected in its Q1 ranking across multiple categories such as Analytical Chemistry and Drug Discovery in 2023, it maintains a high standard in the dissemination of innovative research. The journal not only facilitates the sharing of significant findings but also promotes collaboration and discussion within the community, making a notable impact globally. Articles published in the Journal of Pharmaceutical Analysis are easily accessible under an open-access model, ensuring that cutting-edge research reaches a diverse audience and enhances knowledge in this critical field. As it continues to converge research from 2011 to 2024, the journal remains a cornerstone in the study of pharmaceutical evaluation, analytical methods, and their applications.

DRUG METABOLISM AND DISPOSITION

Your Gateway to Cutting-Edge Drug Research
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0090-9556Frequency: 12 issues/year

Drug Metabolism and Disposition is a premier journal published by the American Society for Pharmacology and Experimental Therapeutics, focusing on crucial advancements in the fields of pharmaceutical sciences and pharmacology. Since its inception in 1973, this esteemed journal has established itself as a leading platform for innovative research, earning a prestigious Q1 rating in both Pharmaceutical Science and Pharmacology categories as of 2023. With an impressive Scopus ranking of #52 out of 183 in Pharmaceutical Science and #105 out of 313 in Pharmacology, it occupies a vital place in an increasingly competitive academic landscape. Researchers, professionals, and students alike benefit from its rigorous peer-reviewed articles that delve into drug metabolism processes and their physiological implications, making it an indispensable resource for anyone aiming to advance their understanding of drug disposition and efficacy. This crucial journal contributes significantly to the ongoing dialogue in pharmacology and toxicology, providing insights that help shape future therapeutic strategies and regulatory policies.

CLINICAL PHARMACOKINETICS

Advancing the Science of Drug Metabolism
Publisher: ADIS INT LTDISSN: 0312-5963Frequency: 12 issues/year

CLINICAL PHARMACOKINETICS, published by ADIS INT LTD, is a premier journal dedicated to the field of pharmacology, with a distinguished reputation since its inception in 1976. With an impressive impact factor and categorized in the Q1 quartile for both general pharmacology and medical pharmacology, this journal ranks #29 out of 272 and #53 out of 313 in its respective categories in Scopus, highlighting its high academic influence and the quality of research it publishes. CLINICAL PHARMACOKINETICS serves as a vital resource for researchers, professionals, and students interested in the latest advancements in drug metabolism, therapeutic efficacy, and clinical applications of pharmacokinetic studies. As it continues to evolve through 2024 and beyond, the journal remains committed to fostering a deeper understanding of pharmacotherapy and its implications in clinical practice. While it does not currently offer open access, the journal ensures that cutting-edge research is accessible through various academic platforms.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Connecting Research to Real-World Applications
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 1567-567XFrequency: 6 issues/year

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, published by Springer/Plenum Publishers, stands as a vital resource in the field of pharmacology. With an ISSN of 1567-567X and an E-ISSN of 1573-8744, this journal is well-regarded within the academic community, as reflected in its Q2 ranking in the 2023 Scopus category for Pharmacology. Spanning years from 1996 to 2024, it serves as a comprehensive platform for cutting-edge research on the interactions of drugs within the body, their effects, and the underlying pharmacological mechanisms. The journal provides a critical avenue for dissemination of significant research findings, with a focus on enhancing understanding in pharmacokinetics, pharmacodynamics, and their implications in therapeutic practices. Targeting an audience of researchers, professionals, and students, the journal emphasizes high-quality manuscripts that contribute to the advancement of knowledge in pharmacology. Although currently not an open access journal, it maintains a strong commitment to promoting scientific communication and collaboration.

ADMET and DMPK

Unlocking the potential of drug development with cutting-edge insights.
Publisher: IAPC PUBLISHINGISSN: 1848-7718Frequency: 4 issues/year

ADMET and DMPK is a premier open-access journal published by IAPC PUBLISHING since 2013, focusing on the rapidly evolving fields of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) and DMPK (Drug Metabolism and Pharmacokinetics). Catering to researchers, professionals, and students in the realms of pharmacology, toxicology, and medicinal chemistry, this journal plays a crucial role in fostering innovation and collaboration within the interdisciplinary landscape of drug development. With an impressive Q1 ranking in Pharmacology, Toxicology and Pharmaceutics and ranking in the top percentiles across various categories such as Chemistry and Health, ADMET and DMPK provides a reputable platform for high-quality publications. Its global reach, complemented by its open-access model, ensures that valuable research is accessible to a wide audience. As we converge towards 2024, this journal remains dedicated to advancing knowledge and practices that shape the future of drug discovery and safety, making it an essential resource in the scientific community.

Expert Opinion on Drug Metabolism & Toxicology

Exploring the Intersection of Drug Development and Safety
Publisher: TAYLOR & FRANCIS LTDISSN: 1742-5255Frequency: 12 issues/year

Expert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.

TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH

Elevating pharmaceutical discourse in tropical regions.
Publisher: PHARMACOTHERAPY GROUPISSN: 1596-5996Frequency: 2 issues/year

Tropical Journal of Pharmaceutical Research is an esteemed open-access platform dedicated to advancing the field of pharmaceutical sciences, published by the Pharmacotherapy Group in Nigeria. With an ISSN of 1596-5996 and open access established since 2002, this journal serves as a critical resource for researchers, professionals, and students seeking to disseminate and access high-quality research in both pharmaceutical science and pharmacology. Despite its ranking in the third quartile (Q3) for Pharmaceutical Science and the fourth quartile (Q4) in Pharmacology as of 2023, the journal continues to stand out with its commitment to fostering significant dialogue and innovation in the scientific community. Anchored at the University of Benin, Faculty of Pharmacy, the journal invites contributions that explore novel pharmaceutical research, clinical applications, and drug development, playing a vital role in addressing health challenges that are particularly relevant to tropical regions. Researchers can look forward to publishing their findings in a journal that not only promotes the sharing of knowledge but also enhances the scientific discourse within a rapidly evolving field.